ClinicalTrials.gg
RecruitingNCT07355842SloW-iRBDUpdated Feb 17, 2026

Role of Slow Waves in the Progression of Neurodegeneration in Isolated REM Sleep Behavior Disorder

An interventional study of Tosoo Axora and Tosoo Axora in Parkinson Disease and REM Sleep Behavior Disorder (iRBD), sponsored by University of Zurich. Recruiting at 1 site in Switzerland. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by University of Zurich · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 85 studies in Parkinson Disease with a site in Switzerland — 31 open to participants now, 34 under way, none of them phase 3. Parkinson Disease · Switzerland.

Planned enrollment
14th of 67
80 · median 30
Started
2026
with 4 others
No phase
49 of 85
23 open now
Primary completion
2029-06
later than 32 of 33 live
Registered
79th of 85
by date
Lead sponsor
8 of 85
University of Zurich

Among the 85 studies in Parkinson Disease with a site in Switzerland, this one is the 14th largest by planned enrollment of the 67 interventional ones that give a count, is one of 5 that started in 2026, is one of 49 with no phase, reaches primary completion later than 32 of the 33 other live ones, and was the 79th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

31 of the 85 studies in Parkinson Disease with a site in Switzerland are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Parkinson Disease with a site in Switzerland, or all of them as a file.
02

Study summary

This study tests whether enhancing deep sleep with gentle sounds at night can slow progression in people with iRBD or early Parkinson's disease. Participants wear a sensor headband and headphones for 18 months. Four assessments including mobility, memory, imaging (PET/MRI), lumbar puncture, and blood tests are assessed.

Read the detailed description

Many people with REM sleep behavior disorder (iRBD) develop Parkinson's disease or similar conditions over the years. To date, there is no effective method to prevent this transition. Animal experiments and observational studies in patients and older adults indicate that deeper sleep is associated with a slower progression of brain changes. In this study, we are now investigating whether enhancement of deep sleep using sounds during sleep can influence the progressive brain changes in iRBD or early Parkinson's disease.

Participants wear a headband with sensors and headphones for 18 months, which plays gentle sounds during sleep to enhance deep sleep. In addition, four examinations are carried out, including tests of mobility, memory, imaging (PET/MRI), a lumbar puncture, and blood sampling. Two of the examinations will take place at the University Hospital of Zurich, and two more can also be carried out at home if desired.

The aim is to investigate whether enhancement of deep sleep can help slow the progression of iRBD or early-stage Parkinson's disease. The study is double-blind and controlled, which means that neither the participants nor the researchers know who is receiving the active treatment.

03

Conditions studied

  • Parkinson Disease
  • REM Sleep Behavior Disorder (iRBD)

Keywords

  • Parkinson
  • Parkinson disease
  • Sleep
  • Neurodegeneration
  • Auditory stimulation
  • iRBD
  • REM sleep behavior disorder
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Diagnosis of polysomnography-confirmed isolated REM Sleep Behavior Disorder (iRBD) based on international criteria (ICSD-3), combined with EITHER
  • UPDRS III without action tremor ≥ 4 AND abnormal olfaction, OR
  • diagnosis of PD along international criteria for less than 2 years

Further inclusion criteria are:

  • no dopaminergic treatment and no foreseen start of such treatment during duration of the study
  • ability to apply the intervention, alone or with help of a co-habitant, stable living situation
  • sufficient language skills in German, French or Italian
  • negative pregnancy test for women of

Exclusion criteria

Exclusion Criteria:

  • Suspected or known non-compliance to other therapies
  • current or recent participation in another clinical trial
  • extended absences
  • hearing impairment that prevents hearing the tones for auditory stimulation
  • non-responder to auditory stimulation during screening
  • concomitant disease or unstable condition
  • Apnea-Hypopnea-Index (AHI) > 15/h or under Continuous Positive Airway Pressure (CPAP) treatment
  • Restless Legs Syndrome
  • meeting criteria for diagnosis of atypical Parkinson syndrome
  • diagnosis of Dementia or (MoCA) \< 24
  • severe Depression or other psychiatric disorder
  • regular use of benzodiazepines and other central nervous system depressant substances
  • current or recent history within the last year of substance abuse disorders or chronic alcohol consumption
  • recent or planned major surgery
  • history of allergies and relevant for electrode application or medication allergies
  • additional exclusion criteria for PET imaging
  • any criterion that may pose the participant at risk
  • breastfeeding, intention to become pregnant, or unwillingness to use medically reliable for women of
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Verum arm

    Nightly enhancement of slow waves through Phase Targeted Auditory Stimulation (PTAS) over 18 months.

    Device: Tosoo Axora

  • Sham comparator
    Sham arm

    Nightly application of tones that will be applied in a non-PTAS manner, resulting in no enhancement of slow waves over 18 months.

    Device: Tosoo Axora

Interventions

  • DeviceTosoo Axora

    Phase Targeted Auditory Stimulation (PTAS) will be applied through integrated headphones with a portable EEG device when non-rapid-eye-movement (NREM) sleep is detected during the night.

    Also known as: PTAS Intervention (Verum)

  • DeviceTosoo Axora

    Auditory stimuli will be delivered during the night through integrated headphones with a portable EEG device in a non-PTAS manner.

    Also known as: PTAS Intervention (Sham)

06

What researchers measure

Primary outcomes

  1. Presynaptic Dopaminergic Integrity

    Striatal dopaminergic function as measured by high-resolution 18F-Fluorodopa (18F-DOPA)-PET imaging.

    Time frame: assessed at Baseline Visit and Closeout Visit (after 18 months)

Secondary outcomes

  1. MDS-UPDRS Part III Score

    Motor symptom severity assessed by the Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS III), a clinician-rated examination of motor signs.

    Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))

  2. Purdue Pegboard Test Score

    Manual dexterity and fine motor coordination assessed by total score on the Purdue Pegboard Test.

    Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))

  3. Alternate Finger Tapping Test

    Motor speed and coordination assessed by performance on the Alternate Finger Tapping Test.

    Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))

  4. UPDRS I.1 (subjective cognition)

    Patient-reported cognitive experiences of daily living assessed by MDS-UPDRS Part I, Item 1.1.

    Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))

  5. Montreal Cognitive Assessment (MoCA) Score

    Global cognitive function assessed by MoCA total score.

    Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout)

  6. Trail Making Test Part A

    Processing speed and attention assessed by time to completion on Trail Making Test Part A.

    Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))

  7. Trail Making Test Part B

    Executive function assessed by time to completion on Trail Making Test Part B.

    Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))

  8. Digit Span Forward

    Attention assessed by Digit Span Forward from the Wechsler Adult Intelligence Scale.

    Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))

  9. Digit Span backward

    Working memory assessed by Digit Span Backward from the Wechsler Adult Intelligence Scale

    Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))

  10. Stroop Test

    Executive function and inhibitory control assessed by Stroop Color-Word Test.

    Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))

  11. Verbal Fluency - Semantic

    Semantic verbal fluency assessed by category fluency task.

    Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))

  12. Benton Judgment of Line Orientation (BJLO)

    Visuospatial function assessed by Benton Judgment of Line Orientation test.

    Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))

  13. LPS-4 Logical Reasoning

    Logical reasoning assessed by Leistungsprüfsystem subtest 4.

    Time frame: assessed at Baseline Visit and Closeout Visit (after 18 months)

  14. Rey-Taylor Complex Figure Test - Copy

    Visuoconstruction assessed by copy trial of the Rey-Taylor Complex Figure Test.

    Time frame: assessed at Baseline Visit and Closeout Visit (after 18 months)

  15. Rey-Taylor Complex Figure Test - Recall

    Visual memory assessed by delayed recall of the Rey-Taylor Complex Figure Test.

    Time frame: assessed at Baseline Visit and Closeout Visit (after 18 months)

  16. California Verbal Learning Test (CVLT)

    Verbal learning and memory assessed by California Verbal Learning Test.

    Time frame: assessed at Baseline Visit and Closeout Visit (after 18 months)

  17. Verbal Fluency - Phonemic

    Phonemic verbal fluency assessed by letter fluency task.

    Time frame: assessed at Baseline Visit and Closeout Visit (after 18 months)

  18. Boston Naming Test (BNT)

    Naming and language function assessed by Boston Naming Test

    Time frame: assessed at Baseline Visit and Closeout Visit (after 18 months)

  19. WAIS Similarities

    Verbal abstract reasoning assessed by similarities subtest from the Wechsler Adult Intelligence Scale

    Time frame: assessed at Baseline Visit and Closeout Visit (after 18 months)

Other outcomes

  1. Exploratory Outcome: Home Sleep EEG - Sleep Microstructure

    NREM sleep oscillatory activity and microstructural features measured by portable EEG device (Tosoo Axora) during nightly use, including but not limited to slow wave activity, sleep spindles, and their temporal dynamics.

    Time frame: Continuous over 18 months

  2. Exploratory Outcome: Home Sleep EEG - Sleep Macrostructure

    Sleep architecture and derived metrics measured by portable EEG device (Tosoo Axora) during nightly use, including sleep stage distribution, sleep continuity, and sleep timing parameters.

    Time frame: Continuous over 18 months

  3. Exploratory Outcome: MRI

    Neuroanatomical and vascular markers assessed by brain MRI, including structural imaging, phase-contrast imaging, arterial spin labeling, and related sequence

    Time frame: assessed at Baseline Visit and Closeout Visit (after 18 months)

  4. Exploratory Outcome: 18F-DOPA PET - Exploratory Parameters

    Exploratory PET parameters including visual assessment of striatal uptake patterns, influx constant (Ki), and F-DOPA distribution beyond predefined regions of interest

    Time frame: assessed at Baseline Visit and Closeout Visit (after 18 months)

  5. Exploratory Outcome: Psychomotor Vigilance Task (PVT)

    Sustained attention and reaction time assessed by the Psychomotor Vigilance Task.

    Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))

  6. Exploratory Outcome: Sustained Attention to Response Task (SART)

    Vigilance and response inhibition assessed by the Sustained Attention to Response Task.

    Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))

  7. Exploratory Outcome: Glucose Metabolism

    Glucose metabolism (HbA1c, glycosylated hemoglobin) will be assessed to explore glucose tolerance and control through a simple blood draw.

    Time frame: assessed at Baseline Visit and Closeout Visit (after 18 months)

  8. Exploratory Outcome - Polysomnography - Sleep Architecture

    Sleep macrostructure including total sleep time, sleep efficiency, and sleep stage distribution assessed by in-laboratory polysomnography.

    Time frame: assessed at Baseline Visit and Closeout Visit (after 18 months)

  9. Exploratory Outcome: Polysomnography - REM Sleep Without Atonia

    REM sleep without atonia (RWA) quantified as percentage of REM sleep with elevated muscle tone on polysomnography.

    Time frame: assessed at Baseline and Closeout (18 months)

  10. Exploratory Outcome: Actigraphy - Sleep-Wake Patterns

    Sleep-wake rhythm including total sleep time, sleep efficiency, and rest-activity patterns assessed by wrist actigraphy over 2-week periods.

    Time frame: assessed before/after each visit (Baseline, after 6 months, after 12 months, Closeout (18 months)) for 2 weeks each

  11. Exploratory Outcome: Sleep Diary

    Self-reported sleep timing, duration, and quality recorded daily over 2-week periods.

    Time frame: Assessed before/after each visit (Baseline, after 6 months, after 12 months, Closeout (18 months)) for 2 weeks each

  12. Exploratory Outcome: Sleep Quality- Visual Analog Scale -

    Subjective sleep quality assessed by Visual Analog Scale.

    Time frame: assessed before/after each visit (Baseline, after 6 months, after 12 months, Closeout (18 months)) for 2 weeks each

  13. Exploratory Outcome - Karolinska Sleepiness Scale (KSS)

    Subjective daytime sleepiness assessed by Karolinska Sleepiness Scale.

    Time frame: assessed before/after each visit (Baseline, after 6 months, after 12 months, Closeout (18 months)) for 2 weeks each

  14. Exploratory Outcome: Retinal Nerve Fiber Layer Thickness (RNFL)

    Retinal nerve fiber layer thickness measured by optical coherence tomography (OCT)

    Time frame: assessed at Baseline Visit and Closeout Visit (after 18 months)

  15. Exploratory Outcome: Ganglion Cell-Inner Plexiform Layer Thickness (GCIPL)

    Ganglion cell-inner plexiform layer thickness measured by optical coherence tomography (OCT)

    Time frame: assessed at Baseline Visit and Closeout Visit (after 18 months)

  16. Exploratory Outcome: Macular Vessel Density (MVD)

    Macular vessel density measured by optical coherence tomography angiography (OCT-A)

    Time frame: assessed at Baseline Visit and Closeout Visit (after 18 months)

  17. Exploratory Outcome: Non-Motor Symptoms Scale (NMSS)

    Non-motor symptom severity and frequency assessed by the Non-Motor Symptoms Scale, a 30-item questionnaire covering nine symptom dimensions

    Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))

  18. Exploratory Outcome: Epworth Sleepiness Scale (ESS)

    Daytime sleepiness assessed by the Epworth Sleepiness Scale (8-item self-report questionnaire)

    Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))

  19. Exploratory Outcome: Parkinson's Disease Sleep Scale-2 (PDSS-2)

    Sleep disturbances assessed by the PDSS-2, a 15-item self-administered questionnaire covering motor problems at night, PD-specific nocturnal symptoms, and disturbed sleep.

    Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))

  20. Exploratory Outcome: Ikelos Rating Scale

    RBD symptom severity assessed by the Ikelos Rating Scale, evaluating frequency and severity of REM sleep behavior disorder

    Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))

  21. Exploratory Outcome: Exploratory Outcome: EQ-5D-5L

    Health-related quality of life assessed by the EQ-5D-5L questionnaire, covering mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, plus visual analogue scale

    Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))

  22. Exploratory Outcome: Blood Biomarkers

    Neurodegenerative and inflammatory markers measured in blood, including neurofilament light chain (NfL) and alpha-synuclein

    Time frame: assessed at Baseline Visit and Closeout Visit (after 18 months)

  23. Exploratory Outcome: CSF Biomarkers

    Neurodegenerative and inflammatory markers measured in cerebrospinal fluid, including amyloid-β, tau, alpha-synuclein, and neurofilament light chain (optional, for participants who consent to lumbar puncture)

    Time frame: assessed at Baseline Visit and Closeout Visit (after 18 months)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jun 2029, 41 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 41 months is above that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2025
First posted
Jan 21, 2026
StartActual
Jan 15, 2026
Primary completionEst.
Jun 30, 2029
CompletionEst.
Jun 30, 2029
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07355842
Collaborators
University Hospital, Zürich
Responsible party
Sponsor
First posted
Jan 21, 2026
Start date
Jan 15, 2026
Primary completion
Jun 30, 2029 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Feb 17, 2026

Study contacts

Jana Bünzli, MSc
Contact
jana.buenzli@usz.ch
+41 44 255 10 43
Marta Menéndez, Dr. phil.
Contact
marta.menendezgranda@usz.ch
+41 43 253 69 54
Andreas Luft, Prof. Dr. med.
principal investigator · University of Zurich

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion